References
- Lu DP. Therapeutics of leukemia. Beijing: Science Press; 1922, p. 152.
- Ribeiro RC, Rego E. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. ASH Educ Program Book 2006;2006:162–8.
- Chang H, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol. 2012;88:321–8.
- Kakizuka A, Miller W Jr, Umesono K, Warrell R Jr, Frankel S, Murty V, et al. Chromosomal translocation t (15; 17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 1991;66:663–74.
- Wang Z-Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505–15.
- Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2007;20:57–65.
- Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005;23:2396–410.
- Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852–60.
- Zhang X-W, Yan X-J, Zhou Z-R, Yang F-F, Wu Z-Y, Sun H-B, et al. Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science 2010;328:240–3.
- Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia. Int J Hematol. 2013;97:717–25.
- Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Canc Inst. 1998;90:124–33.
- Zheng P-Z, Wang K-K, Zhang Q-Y, Huang Q-H, Du Y-Z, Zhang Q-H, et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA 2005;102:7653–8.
- Raffoux E, Rousselot P, Poupon J, Daniel M-T, Cassinat B, Delarue R, et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol. 2003;21:2326–34.
- Shen Z-X, Shi Z-Z, Fang J, Gu B-W, Li J-M, Zhu Y-M, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004;101:5328–35.
- Au W-Y, Kumana CR, Lee HK, Lin S-Y, Liu H, Yeung DY, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood 2011;118:6535–43.
- Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, et al. Outcome of therapy – related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 2011;117:110–5.
- Jiao L, Wang S, Zhuang J, Zhao Y, Zhou D, Xu Y, et al. Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2009;31:555–8.
- Ma X, Ren H, Cen X, Qiu Z, Wang W, Ou J, et al. Efficacy analysis of sequential treatment with chemotherapy, ATRA and As2O3 for acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi 2010;31:328.
- Wang G, Li W, Cui J, Gao S, Yao C, Jiang Z, et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol. 2004;22:63–71.
- Wang H, Chen X-Y, Wang B-S, Rong Z-X, Qi H, Chen H-Z. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Leuk Res. 2011;35:1170–7.
- Wang H, Xi S, Liu Z, Yang Y, Zheng Q, Wang F, et al. Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Environ Toxicol. 2013;28:267–75.
- Hao L, Zhao J, Wang X, Wang H, Wang H, Xu G. Hepatotoxicity from arsenic trioxide for pediatric acute promyelocytic leukemia. J Pediatr Hematol Oncol. 2013;35:e67–70.
- Lin J, Zhu H, Li S, Fan H, Lu X. Complete remission of acute promyelocytic leukemia in a very elderly patient after treatment with low dose arsenic trioxide and sequential retinoic acid: a case report. Ann Hematol. 2014;93(2):335–6.